{"pmid":32427636,"title":"ACE Inhibitors and ARBs in Patients with COVID-19: Friend or Foe?","text":["ACE Inhibitors and ARBs in Patients with COVID-19: Friend or Foe?","Cardiol Rev","Shyh, Grace I","Nawarskas, James J","Cheng-Lai, Angela","32427636"],"journal":"Cardiol Rev","authors":["Shyh, Grace I","Nawarskas, James J","Cheng-Lai, Angela"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427636","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/CRD.0000000000000319","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837748310017,"score":9.490897,"similar":[{"pmid":32413701,"title":"The role of ACEIs/ARBs in COVID-19: Friend or foe?","text":["The role of ACEIs/ARBs in COVID-19: Friend or foe?","Med Hypotheses","Zhou, Zhe","Qiu, Yumin","Tao, Jun","32413701"],"journal":"Med Hypotheses","authors":["Zhou, Zhe","Qiu, Yumin","Tao, Jun"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413701","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109810","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319099891713,"score":87.57471},{"pmid":32292227,"pmcid":"PMC7151242","title":"[Controversy regarding ACE inhibitors / ARBs in Covid-19].","text":["[Controversy regarding ACE inhibitors / ARBs in Covid-19].","Rev Esp Cardiol","Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas","32292227"],"journal":"Rev Esp Cardiol","authors":["Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292227","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.recesp.2020.03.014","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494495358977,"score":77.31805},{"pmid":32371022,"title":"Controversy regarding ACE inhibitors / ARBs in COVID-19.","text":["Controversy regarding ACE inhibitors / ARBs in COVID-19.","Rev Esp Cardiol (Engl Ed)","Soria Arcos, Federico","Romero Puche, Antonio","Vicente Vera, Tomas","32371022"],"journal":"Rev Esp Cardiol (Engl Ed)","authors":["Soria Arcos, Federico","Romero Puche, Antonio","Vicente Vera, Tomas"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371022","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.rec.2020.04.004","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496440467456,"score":77.31805},{"pmid":32472989,"title":"Relationship between ACE-inhibitors, ARBs and SARS-CoV-2 infection: where are we?","text":["Relationship between ACE-inhibitors, ARBs and SARS-CoV-2 infection: where are we?","SARS-CoV-2 is spreading rapidly all over the world. The case fatality rate seems higher in cardiovascular disease and hypertension. Other comorbidities do not seem to confer the same risk, therefore the understanding of the relationship between infection and cardiovascular system could be a crucial point for the fight against the virus. A great interest is currently directed towards the angiotensin 2 converting enzyme (ACE 2) which is the SARS-CoV-2 receptor and creates important connections between the virus replication pathway, the cardiovascular system and blood pressure. All cardiovascular conditions share an imbalance of the renin angiotensin system (RAAS) in which ACE 2 plays a central role. In the last few days, much confusion has appeared about the management of therapy with angiotensin converting enzyme inhibitors (ACE-i) and angiotensin receptor blockers (ARBs) in infected patients and in those at risk of critical illness in case of infection. In this article we will try to reorder the major opinions currently emerging on this topic.","Minerva Cardioangiol","Infusino, Fabio","Cimino, Sara","Lombardi, Marco","Mancone, Massimo","Cavarretta, Elena","Frati, Giacomo","Pugliese, Francesco","Fedele, Francesco","Biondi-Zoccai, Giuseppe","32472989"],"abstract":["SARS-CoV-2 is spreading rapidly all over the world. The case fatality rate seems higher in cardiovascular disease and hypertension. Other comorbidities do not seem to confer the same risk, therefore the understanding of the relationship between infection and cardiovascular system could be a crucial point for the fight against the virus. A great interest is currently directed towards the angiotensin 2 converting enzyme (ACE 2) which is the SARS-CoV-2 receptor and creates important connections between the virus replication pathway, the cardiovascular system and blood pressure. All cardiovascular conditions share an imbalance of the renin angiotensin system (RAAS) in which ACE 2 plays a central role. In the last few days, much confusion has appeared about the management of therapy with angiotensin converting enzyme inhibitors (ACE-i) and angiotensin receptor blockers (ARBs) in infected patients and in those at risk of critical illness in case of infection. In this article we will try to reorder the major opinions currently emerging on this topic."],"journal":"Minerva Cardioangiol","authors":["Infusino, Fabio","Cimino, Sara","Lombardi, Marco","Mancone, Massimo","Cavarretta, Elena","Frati, Giacomo","Pugliese, Francesco","Fedele, Francesco","Biondi-Zoccai, Giuseppe"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472989","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.23736/S0026-4725.20.05271-8","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193434685440,"score":70.99406},{"pmid":32340044,"title":"The ACE-2 in COVID-19: Foe or Friend?","text":["The ACE-2 in COVID-19: Foe or Friend?","COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19.","Horm Metab Res","Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O","32340044"],"abstract":["COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT1R axis and ACE-2-Ang-(1-7)-Mas axis. In metabolic disorders and with increased age, it is known that there is an upregulation of ACE-Ang-II-AT1R axis with a downregulation of ACE-2-Ang-(1-7)-Mas axis. The activated ACE-Ang-II-AT1R axis leads to pro-inflammatory and pro-fibrotic effects in respiratory system, vascular dysfunction, myocardial fibrosis, nephropathy, and insulin secretory defects with increased insulin resistance. On the other hand, the ACE-2-Ang-(1-7)-Mas axis has anti-inflammatory and antifibrotic effects on the respiratory system and anti-inflammatory, antioxidative stress, and protective effects on vascular function, protects against myocardial fibrosis, nephropathy, pancreatitis, and insulin resistance. In effect, the balance between these two axes may determine the prognosis. The already strained ACE-2-Ang-(1-7)-Mas in metabolic disorders is further stressed due to the use of the ACE-2 by the virus for entry, which affects the prognosis in terms of respiratory compromise. Further evidence needs to be gathered on whether modulation of the renin angiotensin system would be advantageous due to upregulation of Mas activation or harmful due to the concomitant ACE-2 receptor upregulation in the acute management of COVID-19."],"journal":"Horm Metab Res","authors":["Dalan, Rinkoo","Bornstein, Stefan R","El-Armouche, Ali","Rodionov, Roman N","Markov, Alexander","Wielockx, Ben","Beuschlein, Felix","Boehm, Bernhard O"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32340044","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1055/a-1155-0501","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494297178112,"score":68.904625}]}